Tumor reductive therapies and antitumor immunity.
Tumor reductive therapies and antitumor immunity.
复制标题
靶向非小细胞肺癌细胞中的 EIF4F 复合物
DOI：
10.18632/oncotarget.18469
复制
发表时间：
2017-08-15
期刊：
影响因子：
--
通讯作者：
Tsung K
中科院分区：
文献类型：
--
作者：
Guo H;Tsung K
肿瘤减量治疗是通过直接杀伤肿瘤细胞来减轻肿瘤负担。到目前为止，还没有关于抗肿瘤免疫与肿瘤减量治疗之间关系的报道。在过去的几年里，出现了一种新的癌症治疗方法--免疫疗法，它们与经典的细胞毒疗法(化疗和放射疗法)分开分类。最突出的例子包括细胞疗法(LAK和CAR-T)和免疫检查点抑制剂(抗PD-1和CTLA-4)。临床免疫疗法的最新进展以及我们对其背后机制的理解表明，这些疗法与经典癌症治疗的关系比我们想象的更密切。在许多情况下，经典疗法的有效性很大程度上受到潜在的抗肿瘤免疫状态的影响。另一方面，免疫疗法在与肿瘤减少疗法相结合时显示出更好的结果，这不仅是因为每种疗法对肿瘤的杀伤作用，而且还因为两种疗法之间的协同作用。一旦我们开始从免疫的角度看待这些经典疗法，许多临床观察就可以解释。我们已经在体内看到了它们对肿瘤抗原的直接作用，它们对抗肿瘤免疫的影响比我们意识到的更大。反过来，抗肿瘤免疫也有助于肿瘤的控制和破坏。本文将从免疫学的角度对经典治疗方法进行综述，总结动物和临床研究的历史和最新发现，提出大多数癌症治疗的最终疗效是通过抗肿瘤免疫发挥的。
Tumor reductive therapy is to reduce tumor burden through direct killing of tumor cells. So far, there is no report on the connection between antitumor immunity and tumor reductive therapies. In the last few years, a new category of cancer treatment, immunotherapy, emerged and they are categorized separately from classic cytotoxic treatments (chemo and radiation therapy). The most prominent examples include cellular therapies (LAK and CAR-T) and immune checkpoint inhibitors (anti-PD-1 and CTLA-4). Recent advances in clinical immunotherapy and our understanding of the mechanism behind them revealed that these therapies have a closer relationship with classic cancer treatments than we thought. In many cases, the effectiveness of classic therapies is heavily influenced by the status of the underlying antitumor-immunity. On the other hand, immunotherapies have shown better outcome when combined with tumor reductive therapies, not only due to the combined effects of tumor killing by each therapy but also because of a synergy between the two. Many clinical observations can be explained once we start to look at these classic therapies from an immunity standpoint. We have seen their direct effect on tumor antigen in vivo that they impact antitumor immunity more than we have realized. In turn, antitumor immunity contributes to tumor control and destruction as well. This review will take the immunological view of the classic therapies and summarize historical as well as recent findings in animal and clinical studies to make the argument that most of the cancer treatments exert their ultimate efficacy through antitumor immunity.
影响因子：
5.2
作者：
Patel MR;Sadiq AA;Jay-Dixon J;Jirakulaporn T;Jacobson BA;Farassati F;Bitterman PB;Kratzke RA
通讯作者：
Kratzke RA